{
  "emaEpar": [
    {
      "activeSubstance": "axitinib",
      "conditionIndication": "Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.",
      "inn": "axitinib",
      "marketingAuthorisationDate": "2012-09-03 00:00:00",
      "marketingAuthorisationHolder": "Pfizer Europe MA EEIG\u00a0",
      "medicineName": "Inlyta",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/inlyta"
    }
  ],
  "fdaDrugLabel": [
    {
      "brand": "INLYTA",
      "indication": "1 INDICATIONS AND USAGE INLYTA is a kinase inhibitor indicated: in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC). ( 1.1 ) in combination with pembrolizumab, for the first-line treatment of patients with advanced RCC. ( 1.1 ) as a single agent, for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. ( 1.2 ) 1.1 First-Line Advanced Renal Cell Carcinoma INLYTA in combination with avelumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC). INLYTA in combination with pembrolizumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma. 1.2 Second-Line Advanced Renal Cell Carcinoma INLYTA as a single agent is indicated for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.",
      "manufacturer": "Pfizer Laboratories Div Pfizer Inc",
      "splSetId": "84137882-e000-47da-bd5b-fa76ab3c76f9"
    },
    {
      "brand": "INLYTA",
      "indication": "1 INDICATIONS AND USAGE INLYTA is a kinase inhibitor indicated: in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC). ( 1.1 ) in combination with pembrolizumab, for the first-line treatment of patients with advanced RCC. ( 1.1 ) as a single agent, for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. ( 1.2 ) 1.1 First-Line Advanced Renal Cell Carcinoma INLYTA in combination with avelumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC). INLYTA in combination with pembrolizumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma. 1.2 Second-Line Advanced Renal Cell Carcinoma INLYTA as a single agent is indicated for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.",
      "manufacturer": "U.S. Pharmaceuticals",
      "splSetId": "8a903e31-936e-4ed7-8a59-59f32374f338"
    }
  ],
  "id": "Axitinib",
  "nciThesaurus": {
    "casRegistry": "319460-85-0",
    "chebiId": "",
    "chemicalFormula": "C22H18N4OS",
    "definition": "An orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect.",
    "fdaUniiCode": "C9LVQ0YUXG",
    "identifier": "C38718",
    "preferredName": "Axitinib",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C159198",
      "C159199",
      "C93259"
    ],
    "synonyms": [
      "AG-013736",
      "AG013736",
      "AXITINIB",
      "Axitinib",
      "Inlyta",
      "N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide",
      "axitinib"
    ]
  }
}